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Abstract
Co-infection with falciparum malaria and leptospirosis is uncommon. The aim of this study is to
report a case of severe sepsis secondary to dual infection with falciparum malaria and leptospirosis.
The literature is also reviewed on the clinical course of such co-infections, and the possible
mechanisms and treatment of patients with life-threatening malaria and leptospirosis with activated
protein C. The patient was a 25-year old male admitted in the Respiratory Intensive Care Unit
(RICU) with fever, haemolysis, acute renal failure, hepatitis, acute lung injury (ALI) and altered
sensorium. A syndromic evaluation was done and investigations revealed falciparum parasitaemia.
He was treated with parenteral artesunate, ceftriaxone and doxycycline, and adjunctive therapies
as for severe sepsis. Infusion of activated protein C was started 20 hours after onset of organ
dysfunction, and intensive haemodialysis was instituted. Over the next four days the patient became
afebrile with progressive resolution of ALI, renal failure and hepatitis. His Leptospira serology
(requested as part of the evaluation) was reported positive on day 5. Dual infections are common
and under-recognized in the tropics. Failure to treat potential co-infections may lead to poor
outcomes. Acute lung injury in falciparum malaria has high mortality rates and therapy as for severe
sepsis may improve survival. Adjunctive therapies, including activated protein C, cannot replace
source eradication.
Background
The world-wide distribution of malaria [1] overlaps with
that of other infectious diseases, including leptospirosis.
Co-infection of malaria with a wide variety of infectious
diseases has been reported. Co-infection of malaria with
leptospirosis is rare and has been only been reported in
seven (two definite and five probable) cases [2]. Clinical
features are unreliable to separate single from dual infec-
tions because of the markedly similar clinical syndrome.
Patients with dual infections have a severe clinical presen-
tation and their clinical course may be worsened by lack
of appropriate therapy for both [2,3]. Patients with severe
falciparum malaria, especially those with acute lung
injury, have a high mortality rate. Falciparum malaria is
due to sequestration of parasites in visceral capillaries
with endothelial dysfunction and leptospirosis is an infec-
tious vasculitis; as a result, therapies which improve
endothelial function might positively impact the clinical
outcomes of both diseases. Newer adjuncts are needed
because of the present high mortality rates and the limited
benefit conferred by current ancillary therapies. Activated
protein C (aPC) has anti-thrombotic, pro-fibrinolytic and
anti-inflammatory properties and confers a relative mor-
tality reduction of 22% in patients with severe sepsis and
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≥ 2 organ dysfunction [4,5] and has recently been
reported to be beneficial in severe falciparum malaria
[6,7] and leptospirosis [7]. This is the first reported case of
severe sepsis secondary to falciparum malaria with lept-
ospirosis co-infection, with good response to aPC in addi-
tion to standard care. Despite the potential benefits of this
therapy, source eradication with appropriate antibiotic
therapy is paramount. Data on the use of aPC in severe
malaria or severe leptospirosis needs to be generated
urgently, but ancillary therapies cannot replace the role of
syndromic evaluation and therapy.
Case report
A 25-year old male was referred to the Department of Pul-
monary Medicine with a short history of high grade fever,
myalgia, cola colored urine, decreased urine output and
shortness of breath. A clinical diagnosis of severe falci-
parum malaria (based on respiratory distress, renal
impairment and haemoglobinuria) had been considered
and he had received two doses of intravenous artesunate
(120 mg). On examination he was found to be drowsy
and febrile; he also had icterus and sub-conjuctival haem-
orrhages. The respiratory rate was 45 breaths/minute,
blood pressure 110/70 mm Hg and heart rate 126 beats/
minute. Auscultation of the chest revealed bilateral crepi-
tations and examination of the abdomen showed hepat-
osplenomegaly. The rest of the examination was
unremarkable. Biochemical investigations revealed a
serum creatinine of 7 mg/dL, serum bilirubin 35 mg/dL
(conjugated fraction 23 mg/dL), serum bicarbonate of 10
mEq/L, plasma haemoglobin (Hb) 24 mg/dL and urine
Hb of 10 mg/dL. Complete blood count showed a haemo-
globin of 9.6 gm/dL, total leucocyte count of 15,600/μL
and platelet count of 98,000/μL). A syndromic diagnosis
of infective hepatorenal syndrome was made and he was
managed in the respiratory intensive care unit with artesu-
nate (150 mg o.d), ceftriaxone (two gm b.i.d) and doxycy-
cline (100 mg b.i.d), stress ulcer and deep venous
thrombosis prophylaxis and intensive blood glucose con-
trol. A thin blood smear was positive for falciparum ring
forms (1.2%) and gametocytes (with reduction in parasi-
taemia possibly due to artesunate given empirically); an
assay for histidine-rich protein 2 obtained simultaneously
was also positive. A clotting profile was normal and his
arterial blood gas revealed combined metabolic and respi-
ratory acidosis (pH 7.12) and hypoxaemia with a PaO2/
FiO2 score of 205. Chest X-ray revealed bilateral peri-hilar
infiltrates suggestive of acute lung injury (Figure 1). His
blood cultures, urine cultures, HEV serology and Weil-
Felix test were negative. Intensive haemodialysis was insti-
tuted for acute renal failure. In view of severe sepsis and
multi-organ dysfunction, an infusion of activated protein
C was also started 20 hours after the onset of organ dys-
function. The patient gradually improved and at 96 hours
he was afebrile, alert with progressive resolution of acute
lung injury (ALI) and hepatitis (Table 1). He remained
oliguric and haemodialysis was continued. IgM ELISA for
leptospira (sent as part of the evaluation) was reported
positive on day 5. Artesunate, ceftriaxone and doxycycline
were continued for seven days. His renal functions started
improving on day 10 and dialysis was discontinued. His
hospital course was complicated by right peroneal palsy
which improved with physiotherapy. He was discharged
on day 14 of hospital admission. Patient was asympto-
matic at two month follow-up.
Discussion
There are about 500 million estimated cases of malaria,
with 2–3 million severe malaria cases and 1.1 million
deaths each year worldwide [8]. Leptospirosis is an
increasingly recognized infection in the tropics. Presence
of the causative agent, farming, poor sanitation and
hygiene provide the substrate for the observed seasonal
epidemics. However, the infection is under-recognized
because most infections are anicteric, resolve spontane-
ously and mimic other febrile illnesses.
Table 1: Physiological and clinical variables during first 7 days of RICU stay demonstrating the effect of the infusion of Drotrecogin alfa 
(activated) on days 1–4.
Variables Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Heart rate (/minute) 128 111 120 116 106 100 92 86
Respiratory rate (/minute) 46 32 36 30 28 28 24 22
Temperature (C) 39 38.5 38.4 38 37 37 37 37.2
pH 7.2 7.25 7.26 7.3 7.34 7.42 7.44 -
PaO2/FiO2 168 180 130 230 260 290 340 -
HCO3 (mEq/L) 13 15 14 18 20 22 22 -
Ventilatory mode Spontaneous ACMV ACMV ACMV PSV T-piece Spontaneous Spontaneous
PEEP (cm H20) - 8 10 6 5 - - -
Serum creatinine (mg/dL) 5.2 6.0 5.2 7.1 4.6 4.4 4.0 3.6
Urine output (mL/24 hours) 460 100 110 200 240 200 270 560
Serum bilirubin (mg/dL) 18.2 18.9 18.2 15.4 9.1 8.4 6.0 4.2
Total leucocyte count (/μL) 19000 19500 18200 14400 11400 8100 8000 8100
Platelet count (/μL) 92000 105,000 155,000 183,000 212,000 241,000 260,000 270,000Malaria Journal 2007, 6:42 http://www.malariajournal.com/content/6/1/42
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In a patient with fever, renal failure and jaundice the dif-
ferential diagnosis include severe malaria, severe lept-
ospirosis, enteric fever, Hantaan virus, viral hepatitis with
fulminant liver failure and scrub typhus [9,10]. The local
epidemiology, presence of haemolysis and lung injury in
this patient restricted the differential diagnosis to malaria,
leptospirosis, typhoid and viral hepatitis (especially HEV
related). These entities may be impossible to resolve clin-
ically and empiric therapy to cover all of these is justified
initially because of the turn-around time of investigations
in the tropics. The patient was started on artesunate, ceftri-
axone and doxycycline accordingly. In a patient with renal
failure and hyperparasitaemia, artesunate has the advan-
tage of rapidity of action, smaller infusion volumes, lesser
toxicity and a mortality reduction of 34.7%[11]. In
patients with severe leptospirosis, doxycycline is as effica-
cious as penicillin[12] and is therapeutic for scrub typhus
as well.
As malaria and leptospirosis are common in the tropics,
co-infections are expected to be common. However such
a scenario has seldom been reported [2,13]. This may be
Chest radiograph shows bilateral perihilar alveolar opacities Figure 1
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due to the unavailability of assays for leptospirosis in
resource-constrained areas and failure to anticipate co-
infections because of the overlapping clinical features. A
significant number of unanticipated co-infections have
been reported when routine syndromic serologic panels
were employed [13]. Failure to recognize acute leptospiro-
sis co-infection causes delay in the initiation of directed
therapy and potentially preventable excess mortality. IgM
ELISA antibodies become detectable by the end of first
week and have replaced MAT (macro-agglutination test)
for routine diagnosis because of the early seroconversion,
availability of commercial bedside kits and excellent sen-
sitivity and specificity [14]. Although this patient had a
modified Faine score [15] of 31 (with > 25 presumptive of
leptospirosis), the validity of this score in co-infections
has not been evaluated. Given the clinical features and
high specificity of IgM ELISA and unavailability of MAT,
the diagnosis of leptospirosis is highly probable.
Acute respiratory distress syndrome in falciparum malaria
has an incidence of 21% in those with severe malaria
requiring hospitalization [16]. Mortality may be as high as
30% in this group and a high frequency of bacterial super-
infections occur [17]. Pulmonary lesions in leptospirosis
are primarily haemorrhagic with an incidence from 20–
70%. The extent of involvement may have no relation to
the presence of icterus and may be self-limited or exten-
sive and fatal.
In patients with severe falciparum malaria, extensive
organ sequestration may lead to endothelial clogging and
dysfunction. Microthrombosis and vasospasm due to
endothelial dysfunction lead to organ hypo-perfusion and
worsening lactic acidosis. Adjunctive therapies like
exchange transfusion [18] and anti-oxidants have shown
no survival advantage [19]. Leptospirosis is an infectious
vasculitis with the potential to accentuate endothelial dys-
function in co-infections. At the time of evaluation of this
patient, a MEDLINE search and communication with
manufacturers (Eli Lilly) revealed no reported data on the
use of aPC in malaria or leptospirosis. Subsequently, five
cases of successful use of aPC in severe malaria and one in
leptospirosis has been reported [6]. This remains the first
report of complicated dual infection treated with aPC. As
the parasitaemia cleared in less than 36 hours of onset of
illness (due to early artesunate institution) exchange
transfusion was not contemplated [18]. He had worsen-
ing organ dysfunction and was initiated on an infusion of
drotrecogin alpha 24 μg/kg/hr for 96 hours and antibiot-
ics. Initiation was guided by the time to establishment of
organ(s) failure and was before 48 hours from the first
organ failure [4]. Drotrecogin alfa treatment has been
shown to reduce mortality in patients with severe sepsis
and has been approved for the treatment of patients with
severe sepsis who have two or more organ dysfunction
and/or APACHE II scores more than 25 [4], and may have
a role in complicated tropical infections as well [7]. An
improvement in respiratory function and more rapid res-
olution of cardiovascular dysfunction has been demon-
strated. Most of these activities appear to involve the
modulation of endothelial function, modulation of leu-
kocyte activity, and improvement in microvascular per-
fusion in severe sepsis, thus improving organ function
[20]. In contrast to sepsis of other aetiologies, the intense
endothelial clogging by malaria and denudation due to
leptospirosis may have contributed to a slower response.
A similar delayed response has been observed in another
reported case [6]. Large trials of use of aPC in malaria and
leptospirosis, though urgently needed, are unlikely to be
conducted given the costs involved. Lack of evidence of
benefit is not evidence of lack of benefit and the use of
aPC in severe falciparum malaria and leptospirosis is jus-
tified pending large trials for the same. Source control rep-
resents a key component of success therapy in sepsis and
is the best way to quickly reduce parasitic or bacterial load
[21]. The appropriate institution of antimicrobials guided
by clinical judgment is thus paramount and cannot be
replaced by ancillary therapies.
Conclusion
Dual infections are common and under-recognized in the
tropics. Clinical features are unreliable to separate single
infections from dual infections, which may have a severe
clinical course. Both falciparum malaria and leptospirosis
are associated with significant endothelial dysfunction
and therapies that improve endothelial function might
positively impact clinical outcomes of both diseases. aPC
has anti-thrombotic, pro-fibrinolytic and anti-inflamma-
tory properties which can improve endothelial function.
Despite the potential benefits of this therapy, source erad-
ication with appropriate antibiotic therapy is paramount.
Data on the use of aPC in severe malaria or severe lept-
ospirosis needs to be generated urgently but the role of
syndromic evaluation and empiric therapy must not be
relegated.
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